微创机器人-B(02252.HK) 公布，根据内部初步统计数据，去年集团旗下腔镜、骨科、血管介入核心产品的综合订单量已累计超过100台。
当中，图迈腔镜手术机器人全球订单达39台，商业化装机突破30台，全球累计商业化订单近60台。鸿鹄骨科手术机器人全球订单达25台，累计订单超过40台，覆盖中国、美国、德国、意大利、比利时、希腊、澳洲及巴西等五大洲的医疗机构。R-ONE血管介入机器人去年12月中标复旦大学附属中山医院等5家上海龙头公立医院的采购订单，国内订单达8台及全球18台。(jl/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-24 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.